Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genzyme's Synvisc-One set for US device panel review

This article was originally published in Scrip

Executive Summary

Genzyme's next-generation viscosupplementation product Synvisc-One will be reviewed by the USFDA's orthopaedic and rehabilitation devices advisory panel on December 9th. Genzyme is seeking an indication for the treatment of pain in patients with osteoarthritis of the knee who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics. The product is longer-acting version of Synvisc (hylan G-F 20), with one intra-articular injection providing six months of pain relief compared with three once-weekly injections for the original product. Genzyme filed the premarket approval application in June 2007. In November 2007 the FDA requested additional analysis and data, and the company responded in June. Genzyme expects FDA action on the application by December 23rd.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts